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Based on observations that for certain cancers, mortality varies according to sun exposure, vitamin D has been proposed to influence
on disease progression. This study aims to investigate whether serum levels of 25(OH)D are associated with prognosis in patients
with prostate cancer. In total, 160 patients with a serum sample in the JANUS serum bank were included. For 123 patients a pre-
treatment serum sample was taken, whereas 37 of the patients had received hormone therapy prior to the blood collection. The
serum level of 25(OH)D was classified as low (o 50nmoll
 1), medium (50–80nmoll
 1) or high (480nmoll
 1). A Cox
proportional hazard regression model was used to assess the association between serum 25(OH)D and cancer mortality. During
follow-up, 61 deaths occurred, of whom 52 died of prostate cancer. The median time of follow-up was 44.0 months (range, 1.2–
154.6). Serum 25(OH)D at medium or high levels were significantly related to better prognosis (RR 0.33; 95% CI 0.14–0.77, RR 0.16;
95% CI 0.05–0.43) compared with the low level. Analysis restricted to patients receiving hormone therapy gave a stronger
association. The serum level of 25(OH)D may be involved in disease progression and is a potential marker of prognosis in patients
with prostate cancer.
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The prehormone vitamin D is well known for its important role in
calcium regulation and mineralisation of the bone. However,
during the last two decades accumulating evidence suggests that
vitamin D also influences several other biological processes. As
early as 1941, an inverse association between ultraviolet radiation
and cancer mortality was suggested (Apperly, 1941). By 1980, the
hypothesis that vitamin D deficiency resulting from insufficient
sun exposure increased mortality from colon cancer was proposed
(Garland and Garland, 1980). The mortality rates for cancer of the
breast, prostate, lung, skin and lymphoma have subsequently been
shown to vary according to variation in sun exposure (John et al,
1999; Freedman et al, 2002; Grant, 2002; Robsahm et al, 2004;
Berwick et al, 2005; Porojnicu et al, 2005, 2007). Results from
recent studies indicate that vitamin D also might influence cancer
incidence (see Giovannucci, 2005) through mechanisms that
influence cancer development and progression and less likely as
a part of the cancer initiation. Vitamin D deficiency is suggested to
be a risk factor for prostate cancer (Schwartz and Hulka, 1990;
Luscombe et al, 2001). The effect of vitamin D on cancer processes
has repeatedly been demonstrated in experimental studies (see
Holick, 2006) as it regulates cell cycle processes such as
proliferation, apoptosis and angiogenesis in different tissues.
Although several factors influence the level of circulating
vitamin D, skin exposure to sunlight is the most important factor.
The main dietary contributors include fatty fish, cod liver oil, eggs,
and vitamin D fortified dairy products. The biologically most
active form of vitamin D, calcitriol (1,25(OH)2D), is formed from
calcidiol (25(OH)D) in the kidney and is kept at a virtually
constant level in serum by parathyroid hormone. However, local
production of 1,25(OH)2D occurs in different tissues including
prostate cells (Schwartz et al, 1998), where it regulates key
processes as cell differentiation and proliferation (Hansen et al,
2001; Omdahl et al, 2002). 1,25(OH)2D acts by binding to nuclear
vitamin D receptors (VDR), and regulates gene transcription. The
amount of vitamin D available in the body is closely associated to
the concentration of the vitamin D metabolite, 25(OH)D, in the
blood. Thus, measurement of circulating 25(OH)D is the best
method to estimate vitamin D availability in the body (Freedman
et al, 2007).
During the winter months at northern latitudes, there is an
insufficient amount of UVB in the sunlight to generate vitamin D
production in the skin. In Norway, the daily maximum UV-indices
vary from zero during the winter months (November–February)
to 4.5–6.5 (possible range 0–10) in the mid-summer (Johnsen
et al, 2002). Similarly, the level of 25(OH)D vary throughout the
year, with a mean in the Norwegian population of about
50nmoll
 1 during the winter to about 70–80nmoll
 1 during the
summer (Moan and Porojnicu, 2006). By using season of diagnosis
as an indicator for the level of vitamin D, we previously have
investigated a possible relationship between vitamin D and cancer-
specific survival. Patients who were diagnosed with cancer of the
breast, colon, prostate, lung or lymphoma during summer or
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sautumn were found to have better prognosis (15–50%) than
patients diagnosed during the winter months (Robsahm et al, 2004;
Porojnicu et al, 2005, 2007). Similar results were observed in a
recent study from the UK, which included more than one million
cancer patients (Lim et al, 2006). A main weakness in these studies
is the ecological study design, only using season of diagnosis as a
proxy of vitamin D.
This study investigates the relationship between vitamin D and
prognosis in patients with prostate cancer, using individual serum
levels of 25(OH)D. The results are discussed in terms of the
hypothesis that vitamin D suppress cancer processes.
MATERIALS AND METHODS
The JANUS serum bank was established in 1973, and has serum
samples from more than 330000 healthy donors. Donors who
developed cancer and were admitted to the Norwegian Radium
Hospital (NRH) for treatment, were asked to donate an additional
serum sample to JANUS. The NRH has national responsibilities for
specialist medicine, including oncology.
This study is based on 160 patients with histologically verified
prostate cancer, diagnosed during the period 1984–2004, who
donated serum samples to JANUS. When admitted to the NRH for
treatment of their prostate cancer these patients donated a second
serum sample to JANUS, which was the inclusion criterion of this
study. The serum samples were collected within 30 days of
hospitalisation at the NRH, and all patients were alive at least 30
days after the date of serum collection. We had no access to the
blood sample taken prior to the cancer disease. A linkage between
the Cancer Registry of Norway and JANUS was made through the
unique personal identification number (PIN) that identifies each
Norwegian citizen. Through this PIN patients were linked to the
National Death Registry, which provided information on the date
and cause of death up to and including 31 December 2005.
Seventy-five microlitres of serum was drawn from each patient’s
sample for the 25(OH)D analyses. The level of circulating 25(OH)D
was measured using a competitive radioimmunoassay (RIA)
(DiaSorin, Stillwater, MN, USA). The RIA is a combined measure
of 25-hydroxyvitamin D3, and 25-hydroxyvitamin D2, which have
similar biological activities. The total analytical coefficient of
variation was between 13–16% for low, medium and high levels of
25(OH)D. Before any further statistical analyses were performed,
the patient’s serum level of 25(OH)D was categorised as follows:
low (below 50nmoll
 1), medium (50–80nmoll
 1), and high
(above 80nmoll
 1). Clinical information about tumour differ-
entiation grade (WHO criteria) (Mostofi, 1980) and functional
status at time of hospitalisation at the NRH, as well as treatment
information, was retrieved from the medical records (NRH).
Functional status was defined as good if performance status,
defined by Eastern Cooperative Oncology Group (Oken et al,
1982), was p2 and less good if the status was 3 or 4. Patient
information from the medical records was collected without the
knowledge of the individual 25(OH)D level.
The patients were split into two groups. Patient group I consists
of 37 patients, who were diagnosed with prostate cancer at another
hospital before the blood donation to JANUS at the NRH. All these
patients were on hormonal treatment when entering the NRH. The
average time between diagnosis and time of 25(OH)D measure-
ment was 2.4 years.The 123 patients included in patient group II
donated the serum sample to JANUS at the time of diagnosis, prior
to any treatment. After blood sampling all these patients received
treatment: radio therapy (n¼20), surgery (n¼29), unspecified
treatment (n¼14) or hormones (n¼60). Altogether, 97 of the 160
patients received hormone therapy. The hormone therapy given
was luteinising hormone-releasing hormone (n¼54), orchiectomi
(n¼26), anti-androgen (n¼9) or other hormones (n¼8). Four
patients received both radiation and hormone therapy.
The patients were followed from the date of 25(OH)D
measurement until date of death, migration or to the end of
follow-up (31 December 2005), whichever occurred first. Cox
proportional hazard regression models (SPSS for Windows,
Version 15.0, 2007) was used to assess the relationship
between serum 25(OH)D level and risk of death from prostate
cancer (cause-specific mortality) and death from all causes
(mortality).
RESULTS
Cause-specific mortality
During the time of follow-up, 61 patients died, of whom 52 died
from prostate cancer. The median time of follow-up was 44.0
months (range, 1.2–154.6). Patient characteristics (age, tumour
differentiation grade, functional status, serum level of PSA) and
25(OH)D measured at the time of hospitalisation at the NRH are
presented for all patients, and for patient group I and II separately
in Table 1.
The upper part of Table 2 shows the relationship between
25(OH)D levels and the risk of death from prostate cancer (group
IþII). The hazard ratios for patients with medium and high levels
of serum 25(OH)D were 0.48 (95% CI: 0.24–0.97) and 0.34 (95%
CI: 0.15–0.77) respectively, compared with the patients with low
serum levels (Model I). For Model II, when patient group and age
were included in the model, patient group status was significant,
but did not influence the estimated effect of 25(OH)D. On adding
tumour differentiation grade and the patient functional status at
the time of blood collection (Model III) a stronger association
between 25(OH)D level and the risk of death from prostate cancer
was observed.
During the time of follow-up, 33 deaths occurred in patient
group I, all due to prostate cancer. The relative risks of dying were
0.31 (95% CI: 0.13–0.73) and 0.26 (95% CI: 0.10–0.68) for patients
with medium or high serum levels of 25(OH)D, respectively,
compared to patients with low 25(OH)D levels (Table 2, Group I).
The results were not substantially altered when age at diagnosis
was included (Model II), but the estimated effect was not
significant after adjusting for tumour differentiation grade and
functional status (Model III).
The last part of Table 2 shows the corresponding results for
patient group II. During follow-up, only 19 patients died of
prostate cancer. When the analysis was adjusted for age (Model II),
tumour differentiation grade and functional status (Model III) a
non-significant lower risk of death from prostate cancer was
observed for patients with high 25(OH)D values.
All 37 patients in group I and 60 of the patients in group II had
received hormone therapy. These 97 patients, of whom 45 died of
prostate cancer, were pooled in a separate analysis (Table 3). The
mean level of 25(OH)D at blood sampling was 70.7 (s.d.¼25.7) in
this group compared with 76.0 (s.d.¼28.1) nmoll
 1 in the group
not receiving any hormones. When age at diagnosis, functional
status and tumour differentiation grade were included in the
analysis, the relative risk of dying from prostate cancer was
0.18 (95% CI: 0.07–0.46) for patients with medium levels of
25(OH)D compared with patients with low levels. For patients
with high serum 25(OH)D, the corresponding result was 0.09
(95% CI: 0.03–0.27).
Overall mortality
Sixty-one patients died during follow-up, the majority from
prostate cancer. The association between the 25(OH)D level and
death from all causes is similar as for cause-specific mortality and
is presented in Table 4 (n¼160).
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sDISCUSSION
Ecological studies provide some evidence of a relationship between
insufficient 25(OH)D levels and cause-specific mortality in patients
with prostate cancer (Robsahm et al, 2004; Lim et al, 2006), and if
substantiated, this may be of importance for the treatment of
prostate cancer patients. The present association study shows a
rather strong relationship between serum levels of 25(OH)D and
cause-specific mortality, especially in the group of patients who
received any type of hormonal treatment.
The strength of this association study is that the observations
are on an individual level and in a relatively young study
population. The median age is 64.5 years, which is about 10 years
younger than the median age at diagnosis for prostate cancer in
Norway. The young age occurs due to the JANUS blood collection
criteria, which allows only patients who previously have donated
serum to the JANUS serum bank, to be included. The patients
relatively of young age might be an advantage, as they may be less
likely to be hospitalised due to health problems related to old age.
Furthermore, there is no reason to believe that the inclusion
criteria into the cohort or other methodological issues are
influenced by the patients’ 25(OH)D level.
A weakness of the study is that some of the patients (group I)
have received hormonal treatment prior to the serum sampling.
Although it is possible that the treatment itself could affect the
patients’ 25(OH)D level, no studies, to our knowledge, have shown
that androgen deprivation therapy can influence the 25(OH)D level
(Greenspan, 2008).
Prostate-specific antigen (PSA) is established as a diagnostic and
prognostic factor within prostate cancer. In this study, information
about individual serum levels of PSA was obtained from the
patient medical records. All the patients had high PSA-levels
(median 17.7mgl
 1). The inclusion of PSA in the analyses did not
affect the estimated hazard ratios when differentiation grade was
included in the analyses (not illustrated). Woo et al (2005)
observed in a pilot study that a high level of 1,25(OH)2D prolongs
the doubling time of PSA, which is in line with our results.
Unfortunately, in this study we have no repeated measurements of
PSA, and hence we were not able to investigate the possible
relationship between 25(OH)D levels and the doubling time of
PSA.
For each patient the 25(OH)D was measured only once; at the
time of hospitalisation. The predictive value of these measure-
ments will depend on the stability of the 25(OH)D by time. In a
reliability study of biomarkers Al-Delaimy et al (2006) show that
the Spearman’s rank correlation coefficients were 0.68 and 0.58 for
25(OH)D measurements taken at 5-year intervals for men and
women, respectively. The authors conclude that no substantial
changes in the mean levels occur over time. Also the time between
blood sampling and measurement could create noise in the
analyses. Lissner et al (1981) have demonstrated a high stability of
frozen human blood serum, under several different conditions.
Further, Tuohimaa et al (2004) claim that storage time does not
influence the vitamin D values in their study. Most of their samples
were from JANUS serum bank and hence treated in the same
manner as the samples in this study.
The disease may, directly or indirectly, have an impact on the
25(OH)D level if patients with advanced disease were less able to
attend outdoor activities or have unsatisfactory dietary habits with
respect to 25(OH)D. This could be the situation in patient group I,
where almost all the patients had metastatic disease at the time of
blood sampling, and where 33 patients died of prostate cancer
during follow-up. However, in this group the median 25(OH)D
level was 62.0nmoll
 1, which is a rather high level and not very
different from the level in the patients with a non-advanced disease
at the time of blood sampling (n¼114; median level 73.0nmoll
 1).
Thus, the disease does not seem to have a strong impact on the
patient’s 25(OH)D level.
In accordance with our hypothesis, the observed association
between 25(OH)D levels and the mortality rate can express a
beneficial effect of holding 25(OH)D levels above a threshold level
(50nmoll
 1). No dose–response relationship was seen. The
differences between the estimates for medium and high serum
25(OH)D were not significant. Although the major part of the
patients included had adequate levels of 25(OH)D, according to
recommendations for bone health, we do not know whether there
is an optimal level with respect to the prostate health. In this small
study including 160 patients in different stages of the disease at
blood sampling, the ranges for the 25(OH)D levels were set to
ensure reasonable group sizes without knowledge about the
patient’s serum level.
There is no general consensus on the optimal level of vitamin D
for maintaining health (Wolpowitz and Gilchrest, 2006). Some
reviews and meta-analyses indicate that there are different
thresholds for various health outcomes (Bischoff-Ferrari et al,
2006; Vieth, 2006; Gorham et al, 2007; Holick, 2007). In this
connection results from two incidence studies should be
mentioned: Tuohimaa et al (2004) demonstrated a J-shaped
dose–effect relationship between vitamin D and prostate cancer
incidence. A recent study by Ahn et al (2008) shows that a high
circulating 25(OH)D level may be associated with an increased risk
Table 1 Patient clinical characteristics at hospitalisation at the NRH for
all patients and patient group I and II separately
Characteristics No. Median Range Frequency (%)
Group I+II 160
Age at diagnosis 160 64.5 52–82
Differentiation grade
a 160
High 35 17.5
Moderate 97 60.6
Low 28 21.9
Calcidiol nmoll
 1 160 72.0 19–162
Low (o50) 29 18.1
Medium (50–80) 82 51.3
High (480) 49 30.6
Functional status 158
Good 145 91.8
Less good 13 8.2
Group I 37
Age at diagnosis 37 66.7 52–79
Differentiation grade
a 37
High 2 5.4
Moderate 18 48.7
Low 17 45.9
Calcidiol nmoll
 1 37 62.0 25–135
Functional status 37 70.3
Good 26 29.7
Less good 11
Group II 123
Age at diagnosis 123 65.7 54–82
Differentiation grade
a 123
High 33 26.8
Moderate 79 64.2
Low 11 9.0
Calcidiol nmoll
 1 123 72.0 19–162
Functional status 121
Good 119 98.3
Less good 2 1.7
aDifferentiation grade of tumour tissue; WHO three-grade system.
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sof aggressive disease. Both studies indicate that high serum levels
of 25(OH)D can be problematic and thus, the general commu-
nication of the result in this study should be done with caution.
The plausibility of an effect of 25(OH)D exists. 25(OH)D can act
as a substrate for the 1,a-hydroxylation and production of
1,25(OH)2D in the prostate or 25(OH)D might bind itself to the
VDR in the prostate cells and act by itself (Schwartz, 2005). Several
experimental studies have demonstrated the anti-invasive and
anti-metastatic effect of vitamin D on prostate cells, through its
promotion of differentiation and apoptosis and its inhibiting effect
on angiogenesis and proliferation (see Dunlap et al, 2003). Our
results are consistent with the ecological studies showing the
lowest death risk among patients diagnosed in seasons with high
ultraviolet radiation exposure (Robsahm et al, 2004; Lim et al,
2006). These results from ecological studies are not in accordance
with an influence of the prostate cancer disease on the level of
vitamin D. The results in the present study are also consistent with
an inverse relationship between plasma 25(OH)D levels and
mortality that have been reported for early-stage lung cancer and
for colorectal cancer (Zhou et al, 2007; Ng et al, 2008).
It has been hypothesised that vitamin D can amplify the effect of
cancer treatment; a synergistic effect that has been observed in
both experimental and clinical studies (Dunlap et al, 2003; Deeb
et al, 2007). Furthermore, results from experimental studies also
indicate an interaction between sexual hormones and vitamin D
metabolism (Nyomba et al, 1987; Sarem and Pedersen, 1988;
Bolland et al, 2007). The androgen testosterone is synthesised from
cholesterol and has a similar structure as vitamin D, and acts
through nuclear receptors that belong to the same chemical family
as VDR. Thus, a possible explanation for the observed association
between 25(OH)D levels and mortality in group I (Table 2) and for
the patients on hormone therapy in groups I and II combined
(Table 3) might be that 25(OH)D amplifies the therapeutic effects
of lowering androgen levels and/or activity and hence improve the
cancer prognosis. Among the patients treated without hormones
only seven patients died of prostate cancer. This makes it
impossible to make an appropriate survival analysis for other
treatments than hormone therapy. The different results between
group I and II (Table 2, model III), might be due to a difference in
the stage of disease. In group II only 19 deaths occurred during
follow-up, which indicate the need for longer follow-up or new
larger studies.
To conclude, this study shows a strong association between
25(OH)D levels and cause-specific mortality in patients with
Table 2 The estimated relationship between serum calcidiol and death
from prostate cancer for all patients and patient group I and II separately
Variables
Model I RR
(95%CI)
Model II RR
(95%CI)
Model III RR
(95%CI)
Group I+II (n¼160)
Calcidiol (nmoll
 1)
Low (o50) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Medium (50–80) 0.48 (0.24–0.97) 0.41 (0.20–0.85) 0.33 (0.14–0.77)
High (480) 0.34 (0.15–0.77) 0.22 (0.09–0.53) 0.16 (0.05–0.43)
Group status 0.05 (0.03–0.10) 0.05 (0.03–0.10)
Age (1 year) 1.00 (0.96–1.03) 1.00 (0.95–1.03)
Differentiation grade
a
High 1.00 (ref)
Moderate 1.56 (0.42–5.06)
Low 7.01 (1.91–25.7)
Functional status
Good 1.00 (ref)
Less good 1.22 (1.00–1.50)
Group I (n¼37)
Calcidiol (nmoll
 1)
Low (o50) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Medium (50–80) 0.31 (0.13–0.73) 0.30 (0.12–0.73) 0.51 (0.14–1.78)
High (480) 0.26 (0.10–0.68) 0.25 (0.09–0.69) 0.41(0.11–1.54)
Age (1 year) 0.99 (0.95–1.04) 0.99 (0.94–1.04)
Functional status
Good 1.00 (ref)
Less good 2.03 (0.61–6.68)
Group II (n¼123)
Calcidiol (nmoll
 1)
Low (o50) Medium 1.00 (ref) 1.00 (ref) 1.00 (ref)
(50–80) 0.73 (0.24-2.24) 1.14 (0.24–5.36) 1.05 (0.21–5.13)
High (480) 0.57 (0.17–1.91) 0.62 (0.11–3.57) 0.59 (0.10–3.47)
Age (1 year) 0.92 (0.85–1.00) 0.93 (0.86–1.00)
Functional status
Good 1.00 (ref)
Less good 1.17 (0.88–1.54)
Differentiation grade
a
High 1.00 (ref)
Moderate 1.60 (0.35–7.34)
Low 4.91 (0.81–29.8)
aDifferentiation grade of tumour tissue; WHO three-grade system.
Table 3 The estimated relationship between serum calcidiol and death
from prostate cancer among patients receiving hormone therapy (n¼97)
Variables
Model I
RR (95%CI)
Model II
RR (95%CI)
Model III
RR (95%CI)
Calcidiol (nmoll
 1)
Low 1.00 (ref) 1.00 (ref) 1.00 (ref)
Medium 0.39 (0.19–0.81) 0.35 (0.17–0.73) 0.18 (0.07–0.46)
High 0.29 (0.12–0.68) 0.20 (0.08–0.50) 0.09 (0.03–0.27)
Group status 0.08 (0.04–0.16) 0.06 (0.02–0.13)
Age (1 year) 1.00 (0.94–1.03)
Functional status
Good 1.00 (ref)
Less good 1.19 (1.04–1.61)
Differentiation grade
a
High 1.00 (ref)
Moderate 0.85 (0.23–3.18)
Low 5.63 (1.42–22.3)
aDifferentiation grade of tumour tissue; WHO three-grade system.
Table 4 The estimated relationship between serum calcidiol and death
from all causes (n¼160)
Variables
Model I
RR (95%CI)
Model II
RR (95%CI)
Model III
RR (95%CI)
Calcidiol (nmoll
 1)
Low 1.00 (ref) 1.00 (ref) 1.00 (ref)
Medium 0.41 (0.21–0.79) 0.37 (0.19–0.73) 0.40 (0.20–0.78)
High 0.35 (0.17–0.2) 0.23 (0.11–0.51) 0.24 (0.11–0.53)
Group status 0.08 (0.05–0.14) 0.08 (0.05–0.14)
Age (1 year) 1.00 (0.97–1.04)
Functional status
Good 1.00 (ref)
Less good 1.32 (1.08–1.61)
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sprostate cancer. The strength of the association indicates that
prostate cancer patients can benefit from increasing the level of
serum 25(OH)D if it is below 50nmoll
 1. However, association
studies do not set out to prove causality and several uncertainties
exist in the present study. A randomised trial should be carried
out, giving the patients vitamin D in addition to the standard
cancer treatment.
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